The Journal of Allergy and Clinical Immunology
Volume 122, Issue 5 , Pages 921-928.e4 , November 2008

Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program

  • Sunita Sharma, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass
    • Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • Corresponding Author InformationReprint requests: Sunita Sharma, MD, Channing Laboratory, 181 Longwood Ave, Boston, MA 02115.
    • ,
  • Augusto A. Litonjua, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass
    • Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Kelan G. Tantisira, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass
    • Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Anne L. Fuhlbrigge, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass
    • Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Stanley J. Szefler, MD

      Affiliations

    • Divisions of Pediatric Clinical Pharmacology, Allergy, and Immunology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colo
    • ,
  • Robert C. Strunk, MD

      Affiliations

    • Division of Allergy and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine and St Louis Children's Hospital, St Louis, Mo
    • ,
  • Robert S. Zeiger, MD, PhD

      Affiliations

    • Department of Allergy, Kaiser Permanente Medical Center, San Diego, Calif
    • ,
  • Amy J. Murphy, PhD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Scott T. Weiss, MD, MS

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Mass
    • Center for Genomic Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass
    • ,
  • Childhood Asthma Management Program Research Group

      Affiliations

    • The members of the research group are listed at the end of the article.

Received 20 February 2008 ,Revised 22 July 2008 ,Accepted 3 September 2008.

References 

  1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–478
  2. Bousquet J, Clark TJ, Hurd S, Khaltaev N, Lenfant C, O'Byrne P, et al. GINA guidelines on asthma and beyond. Allergy. 2007;62:102–112
  3. Abramson MJ, Walters J, Walters EH. Adverse effects of beta-agonists: are they clinically relevant?. Am J Respir Med. 2003;2:287–297
  4. Postma Da DVK, Koeter GH, Sluiter HJ. Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis. 1986;134:276–280
  5. Tantisira KG, Fuhlbrigge AL, Tonascia J, Van Natta M, Zeiger RS, Strunk RC, et al. Bronchodilation and bronchoconstriction: predictors of future lung function in childhood asthma. J Allergy Clin Immunol. 2006;117:1264–1271
  6. Beydon N, M'Buila C, Bados A, Peiffer C, Bernard A, Zaccaria I, et al. Interrupter resistance short-term repeatability and bronchodilator response in preschool children. Respir Med. 2007;101:2482–2487
  7. Tantisira KG, Weiss ST. The pharmacogenetics of asthma: an update. Curr Opin Mol Ther. 2005;7:209–217
  8. Xu X, Weiss ST. Familial aggregation of bronchodilator response: a community-based study. Am J Respir Crit Care Med. 2002;166:774
  9. The Childhood Asthma Management Program Research Group . The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Control Clin Trials. 1999;20:91–120
  10. The Childhood Asthma Management Program Research Group . Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054–1063
  11. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968
  12. Eliasson O, Degraff AC. The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables. Am Rev Respir Dis. 1985;132:858–864
  13. Dales RE, Spitzer WO, Tousignant P, Schechter M, Suissa S. Clinical interpretation of airway response to a bronchodilator. Epidemiologic considerations. Am Rev Respir Dis. 1988;138:317–320
  14. Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest. 2004;126:1875–1882
  15. Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007;119:73–80
  16. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233–242
  17. O'Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet. 2006;368:794–803
  18. Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119:64–72
  19. Deykin A, Wechsler ME, Boushey HA, Chinchilli VM, Kunselman SJ, Craig TJ, et al. Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma. Am J Respir Crit Care Med. 2007;175:228–234
  20. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45–52
  21. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56:1054–1070
  22. Weiss St LA, Lange C, Lazarus R, Liggett SB, Bleeker ER, Tantisira KG. Overview of the pharmacogenetics of asthma treatment. Pharmacogenom J. 2006;6:311–326
  23. Litonjua AA, Silverman EK, Tantisira KG, Sparrow D, Sylvia JS, Weiss ST. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest. 2004;126:66–74
  24. Raby BA, Weiss ST. Beta2-adrenergic receptor genetics. Curr Opin Mol Ther. 2001;3:554–566

 The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. Additional support for this study was provided by grants U01 HL075419, U01 HL65899, P01 HL083069, and T32 HL07427 from the National Heart, Lung, and Blood Institute, National Institutes of Health.

 Disclosure of potential conflict of interest: A. L. Fuhlbrigge has served on the speakers' bureau and respiratory specialist advisory panel for GlaxoSmithKline and Merck, has received funding from Novartis and Sepracor, and has received research grants from Boehringer Ingelheim, GlaxoSmithKline, and Merck. S. J. Szefler has served as a consultant for AstraZeneca, GlaxoSmithKline, Aventis, Genentech, and Merck and has received research grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI); the Childhood Asthma Management Program; NHLBI Childhood Asthma Research and Education; the NIH/NHLBI Asthma Clinical Research Network; the NIH/National Institute of Allergy and Infectious Diseases Inner-City Asthma Consortium; and Ross Pharmaceuticals. R. S. Zeiger has served as a consultant for AstraZeneca, Aerocrine, Merck, Schering-Plough, Genentech, Dynavac, and GlaxoSmithKline and has received research grant from Sanofi-Aventis, GlaxoSmithKline, Genentech and the NHLBI. S. T. Weiss has received research support from the NIH and Genentech. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(08)01562-5

doi: 10.1016/j.jaci.2008.09.004

The Journal of Allergy and Clinical Immunology
Volume 122, Issue 5 , Pages 921-928.e4 , November 2008

Article Tools

* Image Usage & Resolution